This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
David Zacut, MD
Chairman of the Board
Dr. Zacut has served as BrainsWay’s Chairman of the Board of Directors since the company’s inception, and has been providing consulting services to Brain Research Services since May 2001.
Since 1983, Dr. Zacut has been working as a senior practicing physician at Hadassah Hospital, and from 1994 through 2003, he served as a managing director of several large medical centers.
In addition, Dr. Zacut serves as a director of several private companies, including Brain Research Services. Dr. Zacut holds an M.D. degree from the Hebrew University of Jerusalem.